Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech can feel like decoding a medical journal. Alpha Tau Medical’s 10-Ks detail R&D burn rates, 10-Qs outline trial costs, and 8-Ks flag sudden FDA communications—yet these documents often top 200 pages. If you have ever searched for “Alpha Tau Medical insider trading Form 4 transactions” or wondered where the next dilutive offering was disclosed, you know the frustration.
Stock Titan solves the problem. Our AI reads every submission the moment it posts to EDGAR, then serves up succinct explanations, charts, and alerts. Whether you need the “Alpha Tau Medical quarterly earnings report 10-Q filing” or want “Alpha Tau Medical Form 4 insider transactions real-time”, you’ll get AI-powered summaries, red-flag highlights, and downloadable data within seconds. Key tools include:
- Plain-language digests tagged as “Alpha Tau Medical SEC filings explained simply”
- Side-by-side Alpha Tau Medical earnings report filing analysis for trend spotting
- Quick-view cash runway and trial-milestone trackers for understanding Alpha Tau Medical SEC documents with AI
Dig deeper into leadership confidence with Alpha Tau Medical executive stock transactions Form 4, explore pipeline strategy in the Alpha Tau Medical annual report 10-K simplified, review board pay in the Alpha Tau Medical proxy statement executive compensation, and stay ahead of surprises via Alpha Tau Medical 8-K material events explained. From initial lab data to potential commercial launch, every filing is updated in real time and decoded by our expert-trained algorithms, letting you focus on investment decisions instead of document mining.
Alpha Tau Medical Ltd. (DRTS) furnished a Form 6-K noting it issued a press release titled “Alpha Tau Announces Receipt of Radioactive Material License at New Hampshire Manufacturing Facility.”
The submission states the information is being furnished, not deemed filed, and includes the press release as Exhibit 99.1 dated October 21, 2025.
Form 144 notice for Alpha Tau Medical Ltd. (DRTS) reports a proposed sale of 16,000 ordinary shares through Oppenheimer & Co. with an aggregate market value of $72,160. The shares represent a small fraction of the reported 70,380,570 outstanding shares (approximately 0.023%). The securities were acquired on 02/21/2017 under an employee stock options plan and the proposed approximate sale date is 10/01/2025 with payment described as cash upon exercise. The filing indicates no securities sold by the same person in the past three months. Several standard signature and date fields in the remarks section appear in the form but no specific signature, notice date, or plan-adoption date text values are provided in the content supplied.
FAQ
What is the current stock price of Alpha Tau Medical (DRTS)?
What is the market cap of Alpha Tau Medical (DRTS)?
